Cancer Drug Discovery Faces the FACT
Menée à l'aide de xénogreffes, cette étude évalue l'activité antitumorale de petites molécules, appelées curaxines, qui activent p53 et simultanément inhibent NF-kappaB sans engendrer de génotoxicité observable
In this issue of Science Translational Medicine, Gasparian et al. use a clever cell-based screen to identify a family of DNA-binding small molecules—curaxins—that inhibit tumor cell growth and division. The curaxins’ mechanism of action pinpoints a new chromatin-remodeling factor as a therapeutic target for cancer.
Science Translational Medicine , commentaire, 2011